2024
Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis
Odanović N, Schwann A, Zhang Z, Kapadia S, Kunnirickal S, Parise H, Tirziu D, Ilic I, Lansky A, Pietras C, Shah S. Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis. Open Heart 2024, 11: e002852. PMID: 39353703, PMCID: PMC11448144, DOI: 10.1136/openhrt-2024-002852.Peer-Reviewed Original ResearchConceptsCoronary Vasomotor Disorders International Study GroupRate of MACEReduced coronary flow reserveCoronary flow reservePrognosis of patientsVasospastic anginaPatient yearsMyocardial infarctionPrimary outcomeIncidence of primary outcomeLong-term prognosis of patientsSystematic reviewMeta-analysisLong-term prognosisInternational Study GroupAdverse cardiovascular eventsLong-term outcomesImaging stress testsMeta-analysis of studiesRandom-effects modelWeb of ScienceINOCACardiovascular eventsFollow-upVasomotor disorders
2013
Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial)
Caixeta A, Généreux P, Palmerini T, Lansky AJ, Mehran R, Dangas GD, Xu K, Brener SJ, Stone GW. Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial). The American Journal Of Cardiology 2013, 113: 203-210. PMID: 24176063, DOI: 10.1016/j.amjcard.2013.08.035.Peer-Reviewed Original ResearchConceptsMultivessel coronary artery diseaseMajor adverse cardiac eventsSingle-vessel diseasePercutaneous coronary interventionSurgery scoreCoronary interventionClinical outcomesMyocardial infarctionRate of MACETaxus drug-eluting stentsCardiac Surgery (SYNTAX) scoreOverall study cohortAdverse cardiac eventsCoronary artery diseaseDrug-eluting stentsACUITY trialMultivessel diseaseSS tertilesAngiographic predictorsSYNTAX scoreCardiac eventsThird tertileArtery diseaseCardiac deathIndependent predictors
2009
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, Investigators F. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 2009, 374: 1149-1159. PMID: 19717185, DOI: 10.1016/s0140-6736(09)61484-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsFemaleFollow-Up StudiesHemorrhageHeparinHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsRecombinant ProteinsStentsSurvival RateThrombosisTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionNet adverse clinical eventsPercutaneous coronary interventionAdverse clinical eventsBivalirudin groupMajor bleedingClinical eventsControl groupMyocardial infarctionAcute ST-segment elevation myocardial infarctionIIb/IIIa inhibitorsPrimary percutaneous coronary interventionHORIZONS-AMI trialMajor haemorrhagic complicationsPrimary trial endpointRate of MACERate of NACEElevation myocardial infarctionOnset of symptomsAcute myocardial infarctionOptimum treatment strategyWithdrawal of consentThrombin inhibitor bivalirudinImportant clinical implicationsGender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:
Lansky AJ, Ng VG, Mutlu H, Cristea E, Guiran JB, Midei M, Newman W, Sanz M, Sood P, Doostzadeh J, Su X, White R, Cao S, Sudhir K, Stone GW. Gender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:. Catheterization And Cardiovascular Interventions 2009, 74: 719-727. PMID: 19530147, DOI: 10.1002/ccd.22067.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCardiovascular DiseasesCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateLinear ModelsLogistic ModelsMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSex FactorsSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeWomen's HealthConceptsSPIRIT III trialIII trialsXIENCE VTaxus stentXience V stentTVF rateTAXUS paclitaxel-eluting stentRate of MACECoronary artery lesionsStent thrombosis ratesPercutaneous coronary interventionStent late lossPaclitaxel-eluting stentsCoronary stent systemHigher MACEMore hypertensionAngiographic characteristicsArtery lesionsCoronary interventionThrombosis rateAngiographic resultsClinical outcomesClinical benefitStent placementSubset analysis